Bli medlem
Bli medlem

Du är här

2016-06-06

Bionor Pharma ASA: Minutes from the Extraordinary General Meeting 6 June 2016

BIONOR PHARMA ASA

STOCK EXCHANGE ANNOUNCEMENT

Minutes from the Extraordinary General Meeting 6 June 2016

(Oslo, Norway, 6 June 2016) The Extraordinary General Meeting of Bionor Pharma
ASA (OSE:BIONOR) today adopted all items and resolutions as proposed in the
notice.

At the Extraordinary General Meeting, Helene Jebsen Anker was elected as new
board member.

The minutes of the Extraordinary General Meeting is attached hereto.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

Further information

Unni Hjelmaas, Acting CEO, +47 915 19 651, uh@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations&Communications, +45 2030 3903,
jfr@bionorpharma.com

About Bionor

Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing
its proprietary therapeutic vaccine Vacc-4x in combination with other
medicines toward a functional HIV cure. The company believes it has first
mover potential based on clinical results to date and early adoption of now
recognized clinical strategy. In December 2015, Bionor announced that the HIV
'Shock&Kill' trial REDUC with Vacc-4x and romidepsin successfully met its
primary endpoint by reducing latent HIV reservoir and further demonstrated
control of viral load. Bionor is currently planning BIOSKILL, a
proof-of-concept Phase II trial, which may lead to a major value inflection
point and partnering opportunities. Bionor currently retains full ownership
rights to Vacc-4x, i.e., the upside potential from partnering or licensing
remains with the company. Bionor is based in Oslo, Norway and is listed on
Oslo Børs (OSE:BIONOR). More information about Bionor is available
atwww.bionorpharma.com.

Bionor_EGM_Minutes_06062016
http://hugin.info/131219/R/2018260/749117.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bionor Pharma ASA via Globenewswire

HUG#2018260

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.